Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA

Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA

Celyad to Present at Cowen and Company 37th Annual Health Care Conference

Celyad to Present at Cowen and Company 37th Annual Health Care Conference

Celyad Registers First Hematological Patient in CAR-T NKR-2 THINK Trial

Celyad Registers First Hematological Patient in CAR-T NKR-2 THINK Trial

Christian Homsy talked about Celyad on Antipode radio!

Christian Homsy talked about Celyad on Antipode radio!

Celyad retains Piper Jaffray & Co. to explore strategic alternatives relating to its C-Cure® cardiovascular assets

Celyad retains Piper Jaffray & Co. to explore strategic alternatives relating to its C-Cure® cardiovascular assets

Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Celyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2 THINK Trial in Belgium

Celyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2 THINK Trial in Belgium

Celyad Announces USPTO Decision to Uphold US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

Celyad Announces USPTO Decision to Uphold US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

Celyad Announces Registration of the first patient in the Belgian THINK trial

Celyad Announces Registration of the first patient in the Belgian THINK trial

Cardiopoietic cell therapy for advanced IHF-results at 39 week of CHART-1 trial

Cardiopoietic cell therapy for advanced IHF-results at 39 week of CHART-1 trial